GLP-1 receptor agonist ameliorates experimental lung fibrosis
UNIVERSAL IDENTIFIER: http://hdl.handle.net/11093/2103
EDITED VERSION: http://www.nature.com/articles/s41598-020-74912-1
UNESCO SUBJECT: 2410 Biología Humana ; 2499 Otras Especialidades Biológicas ; 32 Ciencias Médicas ; 3205.08 Enfermedades Pulmonares
DOCUMENT TYPE: article
Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, and fatal lung disease. This disease is characterized by an excessive accumulation of extracellular matrix deposition that modify normal lung physiology. Up to date, there are not efficient therapeutic tools to fight IPF. Glucagon-like peptide-1 receptor (GLP-1R) activation plays an essential role in lung functions in normal and in pathological conditions. The aim of the present study was to study the possible beneficial effects of the administration of the GLP-1R agonist, liraglutide, in the pathogenesis of the fibrotic process in an animal model of pulmonary fibrosis induced by bleomycin. We observed that liraglutide decreased mRNA expression of collagen, hydroxyproline and key enzymes for the synthesis of collagen. In addition, GLP-1R activation restored the ACE2 mRNA levels modulating the activities of the RAS components, increased the production of surfactant proteins (SFTPa1, SFTPb, SFTPc) and promoted an improvement in pulmonary and cardiac functionality, including a partial restoration of lung alveolar structure. Liraglutide effects are shown at both the pro-inflammatory and fibrosis phases of the experimental disease. For these reasons, GLP-1 might be regarded as a promising drug for treating pulmonary fibrosis.
Files in this item
- 2020_fandinojuan_scientificrep ...